Literature DB >> 8441327

Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors m1-m4.

S Lazareno1, T Farries, N J Birdsall.   

Abstract

We have studied muscarinic agonist stimulated [35S]GTP gamma S binding and [gamma 32P]GTP hydrolysis (GTPase) in membranes from CHO cells stably transfected with human muscarinic m1-m4 receptors. 'Full' agonists were at least 10-fold more potent at m2 & m4 receptors than at m1 & m3. This pattern was less marked with 'partial' agonists, which had a greater maximal effect at m2 & m4 than at m1 & m3. McN-A343 uniquely was more potent and efficacious at m4 than at m2 receptors. Antagonist affinity constants were estimated by fitting the data from inhibition curves directly to the Schild model. Antagonist affinity estimates were very similar to those measured earlier in binding studies using animal tissues, and confirmed a small degree of m4 selectivity for tropicamide and secoverine. The receptor subtypes activated more than one G-protein subtype; m2 & m4 receptors activated only pertussis (PTX) sensitive G-proteins, while m1 & m3 coupled to both PTX sensitive and insensitive G-proteins. Acetylcholine (ACh) was more potent in stimulating guanine nucleotide exchange in PTX-treated m1 cells than in controls.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8441327     DOI: 10.1016/0024-3205(93)90301-i

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  27 in total

1.  G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype.

Authors:  E C Akam; R A Challiss; S R Nahorski
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

2.  Protein kinase C is involved in M1-muscarinic receptor-mediated facilitation of L-type Ca2+ channels in neurons of the major pelvic ganglion of the adult male rat.

Authors:  A Sculptoreanu; N Yoshimura; W C de Groat; G T Somogyi
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

3.  G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity.

Authors:  N T Burford; D Wang; W Sadée
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

Review 4.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

5.  Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343.

Authors:  Hinako Suga; Gregory W Sawyer; Frederick J Ehlert
Journal:  Mol Pharmacol       Date:  2010-07-19       Impact factor: 4.436

6.  An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.

Authors:  Rajendra Mistry; Mark R Dowling; R A John Challiss
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

7.  Coregulation of natively expressed pertussis toxin-sensitive muscarinic receptors with G-protein-activated potassium channels.

Authors:  Sinead M Clancy; Stephanie B Boyer; Paul A Slesinger
Journal:  J Neurosci       Date:  2007-06-13       Impact factor: 6.167

Review 8.  Activation of G-proteins in brain by endogenous and exogenous cannabinoids.

Authors:  Steven R Childers
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

9.  Modulation of agonist binding by guanine nucleotides in CHO cells expressing muscarinic m1-m5 receptors.

Authors:  P L van Giersbergen; R Leppik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

10.  Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies.

Authors:  S Lazareno; N J Birdsall
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.